The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma

Cancer

Volumn 119, Issue 12, 2013, Pages 2268-2274

  Villaruz, Liza C ^a   Socinski, Mark A ^a   Cunningham, Diana E ^a   Chiosea, Simion I ^b   Burns, Timothy F ^a   Siegfried, Jill M ^b   Dacic, Sanja ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

lung adenocarcinoma; mutant allele specific imbalance; prediction; prognosis; v Ki ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)

Indexed keywords

ANTINEOPLASTIC AGENT; CYSTEINE; GLYCINE;

ADULT; AGED; ALLELIC IMBALANCE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CODON; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; CODON; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878545631     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28039     Document Type: Article

References (22)

1. Howlader N, Noone AM, Krapcho M, et al. eds. SEER Stat Fact Sheets: Lung and Bronchus. Bethesda, MD: National Cancer Institute; 2010. Available at: http://seer.cancer.gov/csr/1975-2008/. [Accessed March 14, 2013.]
2. Herbst RS, Heymach JV, Lippman SM,. Lung cancer. N Engl J Med. 2008; 359: 1367-1380.
3. Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC) [abstract]. J Clin Oncol. 2011; 29 (suppl). Abstract CRA7506.
4. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2005; 92: 131-139.
5. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007; 25: 5240-5247.
6. Camps C, Jantus-Lewintre E, Cabrera A, et al. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. Lung Cancer. 2011; 72: 365-369.
7. Kalikaki A, Koutsopoulos A, Hatzidaki D, et al. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer. 2010; 69: 110-115.
8. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E,. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol. 2012; 30: 3570-3577.
9. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008; 455: 1069-1075.
10. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007; 450: 893-898.
11. Modrek B, Ge L, Pandita A, et al. Oncogenic activating mutations are associated with local copy gain. Mol Cancer Res. 2009; 7: 1244-1252.
12. Soh J, Okumura N, Lockwood WW, et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells [serial online]. PLoS One. 2009; 4: e7464.
13. Engel E,. A new genetic concept: uniparental disomy and its potential effect, isodisomy. Am J Med Genet. 1980; 6: 137-143.
14. Sasaki H, Hikosaka Y, Kawano O, Moriyama S, Yano M, Fujii Y,. Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer. J Thorac Oncol. 2011; 6: 15-20.
15. Hartman DJ, Davison JM, Foxwell TJ, Nikiforova MN, Chiosea SI,. Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival. Int J Cancer. 2012; 131: 1810-1817.
16. Chiosea S, Shuai Y, Cieply K, Nikiforova MN, Dacic S,. EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations. Hum Pathol. 2010; 41: 1053-1060.
17. Guerrero S, Casanova I, Farre L, Mazo A, Capella G, Mangues R,. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res. 2000; 60: 6750-6756.
18. Tsao MS, Hainaut P, Bourredjem A, et al. LACE-Bio pooled analysis of the prognostic and predictive value of KRAS mutation in completely resected non-small cell lung cancer (NSCLC) [abstract]. Ann Oncol. 2010; 21 (suppl). Abstract 4218.
19. Shepherd FA, Bourredjem A, Brambilla E, et al. Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): a LACE-Bio study [abstract]. J Clin Oncol. 2012; 30 (suppl). Abstract 7007.
20. Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012; 104: 228-239.
21. Chiosea SI, Sherer CK, Jelic T, Dacic S,. KRAS mutant allele-specific imbalance in lung adenocarcinoma. Mod Pathol. 2011; 24: 1571-1577.
22. Oakley GJ 3rd, Chiosea SI,. Higher dosage of the epidermal growth factor receptor mutant allele in lung adenocarcinoma correlates with younger age, stage IV at presentation, and poorer survival. J Thorac Oncol. 2011; 6: 1407-1412.